Evoxac Related Published Studies
Well-designed clinical trials related to Evoxac (Cevimeline)
Effectiveness of cevimeline to improve oral health in patients with postradiation
xerostomia. [2012]
Comparison of the effects of pilocarpine and cevimeline on salivary flow. [2009.05]
Well-designed clinical trials possibly related to Evoxac (Cevimeline)
Treatment of primary Sjogren syndrome: a systematic review. [2010.07.28]
Other research related to Evoxac (Cevimeline)
Cevimeline (Evoxac (R)) overdose. [2011.03]
Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations. [2010.01.04]
Sjogren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment. [2009]
The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjogren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. [2008.04]
Cevimeline. [2008]
Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. [2007.12.01]
The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjogren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. [2007.09.26]
Efficacy prediction of cevimeline in patients with Sjogren's syndrome. [2007.08]
Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. [2007.07.15]
Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice. [2007.05]
Cevimeline for the treatment of postirradiation xerostomia in patients with head-and-neck cancer. [2007.03.20]
Effects of cevimeline on salivation and thirst in conscious rats. [2007.01]
Effect of cevimeline on salivary components in patients with Sjogren syndrome. [2005.05]
Other possibly related research studies
Assessment of the use of sialogogues in the clinical management of patients with xerostomia. [2006.07]
Management of xerostomia related to radiotherapy for head and neck cancer. [2005.12]
Xerostomia secondary to Sjogren's syndrome in the elderly: recognition and management. [2005]
Salivary hypofunction and xerostomia: diagnosis and treatment. [2005.04]
The management of Sjogren's syndrome. [2006.05]
Recent advances in the management of ocular complications of Sjogren's syndrome. [2005.07]
Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. [2007.03]
Xerostomia: causes and treatment. [2007.12]
The therapy of Sjogren's syndrome: a review. [2007.09]
Effect of a muscarinic M3 receptor agonist on gastric motility. [2007.11]
[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjogren's syndrome.] [2007.02]
M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. [2007.12]
Therapeutic targets in dry eye syndrome. [2008.04]
Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. [2008.06]
Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. [2008.06]
Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. [2009.03.01]
The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren's syndrome. [2010.07]
Treatment of Sjogren's syndrome-associated dry eye an evidence-based review. [2011.07]
|
